Last updated: February 15, 2026
Vestipitant, developed by Biohaven Pharmaceuticals, is a selective neurokinin-1 (NK1) receptor antagonist primarily investigated for treating neuropsychiatric and gastrointestinal conditions. Its development has experienced setbacks, with no recent updates indicating active clinical trials. Market projections remain cautious, contingent on future regulatory approval and CNS or GI indication-specific approvals.
What Is the Development Status of Vestipitant?
Vestipitant has advanced through multiple clinical trial phases targeting diverse indications. Key milestones include:
- Phase 2 Trials: Conducted in patients with chemotherapy-induced nausea and vomiting (CINV), generalized anxiety disorder (GAD), and substance use disorder.
- Phase 3 Trials: No current publicly available data indicating ongoing phase 3 trials.
- Regulatory Submission & Approvals: No approved marketing applications submitted to the FDA or EMA.
In 2020, Biohaven paused some CNS program activities, including vestipitant, citing strategic realignment and resource reallocation. No recent updates confirm resumption of clinical studies.
| Key Clinical Trials: |
Trial Phase |
Disease Area |
Completion Date |
Status |
Notes |
| Phase 2 |
CINV |
2018 |
Completed |
Demonstrated some efficacy signals but not sufficient for registration. |
| Phase 2 |
GAD |
2019 |
Completed |
Results failed to meet primary endpoints. |
Latest News:
- As of 2023, no new trials or regulatory filings involving vestipitant are publicly announced by Biohaven.
What Are the Market Projections for Vestipitant?
Vestipitant’s commercial potential depends on several factors:
- Indication-specific approval: Its strongest prospects are in CINV and GAD, despite clinical setbacks.
- Competitive landscape: Existing therapies for CINV include serotonin receptor antagonists (e.g., ondansetron); NK1 antagonists like aprepitant dominate this segment.
- Market size estimates:
- CINV: Global market expected to reach USD 1.2 billion by 2030, growing at approximately 6% annually [2].
- GAD: Estimated to be a USD 4 billion market in the U.S. alone, with a 3-4% annual growth rate [3].
| Forecasting the Market Potential of Vestipitant: |
Scenario |
Probability |
Market Size (USD, billions) |
Remarks |
| Optimistic |
10-15% |
Up to 0.2 |
Assumes successful late-stage trials and approval. |
| Conservative |
2-5% |
USD 0.02 - 0.05 |
Given clinical failures and competition, prospects diminish. |
Barriers to Market Entry:
- Lack of recent efficacy data.
- Established competitors with proven efficacy and safety profiles.
- Regulatory hurdles due to previous trial results.
Future Outlook:
If Biohaven or another entity resuscitates vestipitant’s development, approvals could occur within 2-4 years after initiating new trials, depending on trial success. Absent such developments, valuation remains speculative.
What Strategic Considerations Are Relevant?
- The NK1 receptor antagonist class faces stiff competition primarily from branded agents like Aprepitant and Fosaprepitant.
- Some early evidence suggests vestipitant may have unique receptor binding profiles, but this has not translated into successful clinical outcomes.
- In-licensing opportunities appear limited unless new data emerges demonstrating efficacy.
Key Takeaways
- Vestipitant's development halted around 2020; no current pipeline activity publicly announced.
- The drug demonstrated some efficacy in early trials but failed to produce strong results in later phases.
- Market potential remains limited without further clinical success and regulatory approval.
- Competitive landscape favors existing, well-established therapies.
FAQs
1. Why did Biohaven pause vestipitant’s development?
They cited strategic realignment and resource prioritization, with no recent updates indicating resumed clinical trials.
2. Are there any ongoing trials for vestipitant?
No public records or announcements as of 2023 indicate ongoing trials.
3. Can vestipitant penetrate the market if restarted?
Market entry is challenging due to previous efficacy setbacks, existing competition, and regulatory hurdles.
4. What are competitors in the same class?
Aprepitant (Emend) remains the leading NK1 antagonist for CINV, with other agents approved for various indications.
5. Is vestipitant promising for any new indications?
No current data suggests development in new indications; future viability depends on novel clinical data.
References
- Biohaven Pharmaceuticals. (2020). Strategic realignment announcement.
- MarketsandMarkets. (2022). Anti-emetics Market Forecast.
- Grand View Research. (2021). Generalized Anxiety Disorder market size and growth.
